Access is not a downstream function. It’s the lens through which evidence, value, price and strategy must be designed.
In a world shaped by JCA, MFN, and pricing convergence, launch sequencing, portfolio choices, and pricing strategy only matter if they hold up to access scrutiny. From evidence to price to launch, access determines what works, what scales, and what is valued.
That’s why at Acumetis, access isn’t a service offering — it’s how we work. We bring clarity, judgment, and senior accountability to the decisions that shape commercialization success, connecting strategy across functions and across the lifecycle so nothing falls between the gaps.
Most organize access by region. We organize it around global decisions informed by country reality — linking US pricing, EU HTA requirements, and local payer expectations into a single decision logic so early choices remain defensible everywhere they land.
Designing strategy from early decision to launch
A fully integrated approach built for real-world complexity so the decisions that shape access are made with clarity and confidence, from pipeline to launch and beyond.
Diligence & Pipeline Planning
Reframing asset potential and go/no go decisions using our deep insight
- Landscape analysis
- Rapid expert assessment
- Early and HTA Scientific advice
- Indication prioritization
Launch Strategy & Go-to-Market
Planning tailored to each asset and company whatever the launch model
- Landscape analysis, gap analysis and evidence strategy
- Forecast modelling
- Go to next stage decisions
- Launch sequence and planning
Value Communication & Policy
Translating complex evidence into compelling value stories that resonate with payers, HTA bodies, and policy stakeholders
- Evidence strategy
- Global and regional value dossiers
- Value proposition and message development
- Publication strategy and policy engagement
Evidence Synthesis
Systematically identify, evaluate and combine data to generate robust, transparent and decision-ready inputs for policy, clinical and economic evaluations.
- Health economic modeling
- Literature reviews
- Indirect comparisons
- Structured elicitation
HTA Submissions
The total solution for your access HTA journey: tailored support from single to multi-country submissions with seamless delivery
- Early and HTA scientific advice
- HTA submissions, including JCA
- Global & country submission dossiers
- Reimbursement negotiation support
Capability Transformation
Equipping organisations for future access success; negotiation, organization change and reframing challenges
- Business process design and facilitation
- Collaborative negotiation training
- Competency mapping and tailored development
- Cross functional global, regional, and local workshops
Senior experts, in your corner
Integrated across the full lifecycle
Pricing strategy, launch sequencing, medical evidence, and portfolio decisions need to hold up to access scrutiny. We embed access expertise across every function and every stage of the asset lifecycle, connecting evidence, value, price, and strategy so your team is always acting with a shared view of what’s required to achieve commercialization success.
JCA sets the evidence reality. A single EU clinical assessment means teams need to ask earlier whether they are truly JCA ready, not just EMA ready, and whether the assessment will translate to desired local access. Acumetis helps clients treat JCA as a pivotal strategic test, not a process to manage – connecting strategic clarity, critical connection, and reframing challenges so global, regional, and local decisions are made earlier, clearer, and built to hold up under access scrutiny.
Clinical development & pre-launch
Ensure access logic shapes development before decisions are locked in with diligence and pipeline planning, indication prioritization, landscape and gap analysis, and early scientific advice.
Launch & growth
Sharpen the story with HTA submissions, JCA readiness, health economic modelling, and value communication strategy aligned to what payers need and timed to maximize benefit ratings.
Launch & beyond
Protect and sustain value with Launch sequence planning, reimbursement negotiation support, pricing governance, and capability transformation that ensures your access strategy holds up as markets evolve.
